The global fiducial markers market size is estimated to reach USD 142.0 million by 2027 registering a CAGR of 4.2%, according to a new report by Grand View Research, Inc. Increasing prevalence of cancer and growing adoption of radiotherapy procedures are the factors expected to contribute to the market growth. Fiducial markers are widely used in external beam radiotherapy procedures. Therefore, increasing number of external beam radiotherapy procedures is also expected to boost the adoption of these markers. In addition, over most of the cancer patients receive radiation therapy, which in turn, is increasing the product demand.
Rising awareness about the safety and efficiency of advanced radiotherapy techniques, such as stereotactic radiosurgery, intensity-modulated radiotherapy, and image guide radiotherapy, in cancer treatment is expected to boost the market growth. Moreover, several initiatives undertaken by various governments for the development of new radiotherapy centers through direct funding or tax waive-off will aid in market growth.
On the other hand, availability of alternative treatment methods, such as chemotherapy, hormonal therapy, and surgery, is expected to have a negative impact on the product demand. Furthermore, with the advent of advanced imaging modalities, such as PET-based LINAC system, eliminates the need for fiducial markers hampering the market growth. However, high cost of PET-based LINAC systems is expected to contribute to the increased usage of fiducial markers for radiotherapy.
To request a sample copy or view summary of this report, click the link below:
Further key findings from the study suggest:
Gold fiducial markers segment held the largest market share in 2019 and is expected to expand at a healthy CAGR over the forecast period owing to product advantages, such as biocompatibility and enhanced visibility across multiple imaging modalities including CT, MRI, ultrasound, and fluoroscopy.
Based on application, prostate cancer segment held the largest market share in 2019 and is expected to register a significant CAGR over the forecast period.
Based on end user, radiotherapy center segment is projected to register the fastest CAGR during the forecast period.
North America is estimated to be the largest regional fiducial markers market over the forecast period due to growing number of cancer cases and adoption of advanced technologies.
Some of the prominent companies in the global market are CIVCO Radiotherapy; IZI Medical Products, LLC; Naslund Medical AB; Medtronic PLC; QlRad, Inc.; QFIX; Boston Scientific Corp.; Nanovi A/S; Eckert & Ziegler; and IBA Dosimetry GmbH.